文献速递心脑血管急症

阿利西尤单抗与急性冠脉综合征后的心血管结局

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
PubMed 文献 · N Engl J Med · 2018-11-07
一句话结论急性冠脉综合征后1-12个月、已接受高强度他汀治疗且LDL-C≥70 mg/dL的患者,阿利西尤单抗75 mg皮下注射每2周1次可降低复合心血管事件风险(HR 0.85)。

ODYSSEY OUTCOMES为多中心、随机、双盲、安慰剂对照试验,纳入18,924例1-12个月前发生急性冠脉综合征、已接受高强度他汀或最大耐受剂量他汀治疗、且LDL-C≥70 mg/dL(1.8 mmol/L)或非HDL-C≥100 mg/dL(2.6 mmol/L)或载脂蛋白B≥80 mg/dL的患者。患者随机接受阿利西尤单抗75 mg皮下注射每2周1次(9462例)或匹配安慰剂(9462例),盲法下调整剂量以使LDL-C达25-50 mg/dL(0.6-1.3 mmol/L)。中位随访2.8年,主要复合终点(冠心病死亡、非致死性心肌梗死、致死或非致死性缺血性卒中、需住院的不稳定型心绞痛)在阿利西尤单抗组903例(9.5%)vs 安慰剂组1052例(11.1%)(HR 0.85;95%CI 0.78-0.93;P<0.001)。全因死亡阿利西尤单抗组334例(3.5%)vs 安慰剂组392例(4.1%)(HR 0.85;95%CI 0.73-0.98)。基线LDL-C≥100 mg/dL者绝对获益大于基线水平较低者。不良事件两组相似,除局部注射部位反应(阿利西尤单抗组3.8% vs 安慰剂组2.1%)。

要点

  • 急性冠脉综合征后1-12个月、已接受高强度他汀或最大耐受剂量他汀、LDL-C≥70 mg/dL(1.8 mmol/L)或非HDL-C≥100 mg/dL(2.6 mmol/L)或载脂蛋白B≥80 mg/dL的患者,阿利西尤单抗75 mg皮下注射每2周1次降低主要复合终点(9.5% vs 11.1%;HR 0.85;95%CI 0.78-0.93;P<0.001)。
  • 全因死亡阿利西尤单抗组3.5% vs 安慰剂组4.1%(HR 0.85;95%CI 0.73-0.98)。
  • 基线LDL-C≥100 mg/dL的患者绝对获益大于基线LDL-C较低者。
  • 阿利西尤单抗组局部注射部位反应3.8% vs 安慰剂组2.1%,其余不良事件两组相似。
  • 阿利西尤单抗剂量在盲法下调整,目标LDL-C 25-50 mg/dL(0.6-1.3 mmol/L)。

适用人群与场景

  • 1-12个月前发生急性冠脉综合征的患者
  • 已接受高强度剂量他汀或最大耐受剂量他汀治疗
  • LDL-C≥70 mg/dL(1.8 mmol/L)或非HDL-C≥100 mg/dL(2.6 mmol/L)或载脂蛋白B≥80 mg/dL

诊断标准与关键阈值

  • LDL-C≥70 mg/dL(1.8 mmol/L)或非HDL-C≥100 mg/dL(2.6 mmol/L)或载脂蛋白B≥80 mg/dL
  • 阿利西尤单抗剂量调整目标:LDL-C 25-50 mg/dL(0.6-1.3 mmol/L)

处置流程与药物剂量

  • 阿利西尤单抗75 mg皮下注射每2周1次,盲法下调整剂量以使LDL-C达25-50 mg/dL(0.6-1.3 mmol/L)
  • 对照为匹配安慰剂每2周1次

研究设计与关键结果

  • 多中心、随机、双盲、安慰剂对照试验,纳入18,924例,阿利西尤单抗组9462例 vs 安慰剂组9462例,中位随访2.8年
  • 主要复合终点(冠心病死亡、非致死性心肌梗死、致死或非致死性缺血性卒中、需住院的不稳定型心绞痛):阿利西尤单抗组903例(9.5%)vs 安慰剂组1052例(11.1%)(HR 0.85;95%CI 0.78-0.93;P<0.001)
  • 全因死亡:阿利西尤单抗组334例(3.5%)vs 安慰剂组392例(4.1%)(HR 0.85;95%CI 0.73-0.98)
  • 基线LDL-C≥100 mg/dL者绝对获益大于基线LDL-C较低者
  • 不良事件两组相似,局部注射部位反应阿利西尤单抗组3.8% vs 安慰剂组2.1%

证据类型、等级与局限

  • 证据类型:多中心、随机、双盲、安慰剂对照试验
  • 局限:原文未报告局限性

对床旁实践的改变

  • 对于急性冠脉综合征后1-12个月、已接受高强度他汀或最大耐受剂量他汀、LDL-C≥70 mg/dL(1.8 mmol/L)或非HDL-C≥100 mg/dL(2.6 mmol/L)或载脂蛋白B≥80 mg/dL的患者,阿利西尤单抗75 mg皮下注射每2周1次降低主要复合终点风险(HR 0.85;95%CI 0.78-0.93)
  • 基线LDL-C≥100 mg/dL的患者绝对获益大于基线LDL-C较低者
  • 需注意局部注射部位反应(阿利西尤单抗组3.8% vs 安慰剂组2.1%)

指南或共识出处

  • ODYSSEY OUTCOMES试验(ClinicalTrials.gov NCT01663402),由Sanofi和Regeneron Pharmaceuticals资助

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events. We sought to determine whether alirocumab, a human monoclonal antibody to proprotein convertase subtilisin-kexin type 9 (PCSK9), would improve cardiovascular outcomes after an acute coronary syndrome in patients receiving high-intensity statin therapy.

METHODS: We conducted a multicenter, randomized, double-blind, placebo-controlled trial involving 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier, had a low-density lipoprotein (LDL) cholesterol level of at least 70 mg per deciliter (1.8 mmol per liter), a non-high-density lipoprotein cholesterol level of at least 100 mg per deciliter (2.6 mmol per liter), or an apolipoprotein B level of at least 80 mg per deciliter, and were receiving statin therapy at a high-intensity dose or at the maximum tolerated dose. Patients were randomly assigned to receive alirocumab subcutaneously at a dose of 75 mg (9462 patients) or matching placebo (9462 patients) every 2 weeks. The dose of alirocumab was adjusted under blinded conditions to target an LDL cholesterol level of 25 to 50 mg per deciliter (0.6 to 1.3 mmol per liter). The primary end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization.

RESULTS: The median duration of follow-up was 2.8 years. A composite primary end-point event occurred in 903 patients (9.5%) in the alirocumab group and in 1052 patients (11.1%) in the placebo group (hazard ratio, 0.85; 95% confidence interval [CI], 0.78 to 0.93; P<0.001). A total of 334 patients (3.5%) in the alirocumab group and 392 patients (4.1%) in the placebo group died (hazard ratio, 0.85; 95% CI, 0.73 to 0.98). The absolute benefit of alirocumab with respect to the composite primary end point was greater among patients who had a baseline LDL cholesterol level of 100 mg or more per deciliter than among patients who had a lower baseline level. The incidence of adverse events was similar in the two groups, with the exception of local injection-site reactions (3.8% in the alirocumab group vs. 2.1% in the placebo group).

CONCLUSIONS: Among patients who had a previous acute coronary syndrome and who were receiving high-intensity statin therapy, the risk of recurrent ischemic cardiovascular events was lower among those who received alirocumab than among those who received placebo. (Funded by Sanofi and Regeneron Pharmaceuticals; ODYSSEY OUTCOMES ClinicalTrials.gov number, NCT01663402 .).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018. PMID: 30403574. doi:10.1056/NEJMoa1801174

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。